Pharmacyclics, Inc. (PCYC), Johnson & Johnson (JNJ) File for Marketing Approval for Ibrutinib

Page 2 of 2

Around 113,000 patients in the U.S. have chronic lymphocytic leukemia. More than 15,000 new patients are diagnosed with the disease every year. There are around 5,000 new diagnoses of mantle cell lymphoma in the U.S. annually.

If ultimately approved, ibrutinib could prove to be very successful for Pharmacyclics, Inc. (NASDAQ:PCYC) and Johnson & Johnson (NYSE:JNJ). Piper Jaffray estimates that the drug could hit annual sales of more than $4 billion for just the chronic lymphocytic leukemia indication.

The article Pharmacyclics, Johnson & Johnson File for Marketing Approval for Ibrutinib originally appeared on Fool.com.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2